oxfendazole
Article
oxfendazole is a recurring concept in the Astral Codex Ten archive, appearing 3 times across 3 issues between December 08, 2023 and June 18, 2025. The archive places it in contexts such as “Development of oxfendazole”; “antiparasitic drug oxfendazole has been approved for Phase 2 trials”; “clinical study of oxfendazole’s efficacy in human patients”. It most often appears alongside ACX, ACX Grants, AI Safety.
Metadata
- Category: Concepts
- Mention count: 3
- Issue count: 3
- First seen: December 08, 2023
- Last seen: June 18, 2025
Appears In
Related Pages
-
- ACX (2 shared issues)
-
- ACX Grants (2 shared issues)
-
- AI Safety (2 shared issues)
-
- Anthropic (2 shared issues)
-
- Congress (2 shared issues)
-
- effective altruism (2 shared issues)
-
- FDA (2 shared issues)
-
- Kentucky (2 shared issues)
-
- Manifold Markets (2 shared issues)
-
- Manifund (2 shared issues)
-
- Oxfendazole (2 shared issues)
-
- Peru (2 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
Development of oxfendazole, a drug for treating parasitic worms in developing countries.
21: Updates from ACX grantees: antiparasitic drug oxfendazole has been approved for Phase 2 trials (ie trials in humans) in Peru. And Dr. Roy and his citizen drinking water surveillance project have published a paper discussing some of their work over the past decade.
11: Develop Oxfendazole As A New Deworming Medication
Drug development is a highly regulated process; it is not glitzy. But this necessary path to bring a new medicine to deworming efforts world-wide is no the less important because of having to follow a prescribed pathway. To this end and because of the largesse of donors, we have completed several nonclinical studies on oxfendazole itself, on its physical chemical properties, and on its potential for toxicity in a rodent and a non-rodent species.
These studies support our clinical work, following successful completion of two Phase I studies. We are presently collaborators on three Phase II efficacy studies taking place in Peru on three different parasitic diseases, an approach to ascertain the range (in terms of disease and dose) of oxfendazole’s efficacy.